News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

04.09.2019 | Atriva Therapeutics GmbH

Atriva Therapeutics takes part in four conferences in the upcoming months

Dr. Rainer Lichtenberger, CEO of Atriva, will represent the Company and will be available for networking and one-on-one meetings at the following events:

28.08.2019 | immatics biotechnologies GmbH

Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today anno...
27.08.2019 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

Retina-on-a-chip provides powerful tool for studying eye disease

Impact statement: New technology that recreates some of the complexity of the human retina may help scientists study eye disease and screen for drug side effects that harm the eye.

13.08.2019 | CureVac AG

CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered into a Collaborative Research Agreement ...
13.08.2019 | Insilico Biotechnology AG

Predictive Digital Twins control bioprocesses for the production of monoclonal antibodies

Insilico Biotechnology AG and the Laboratory of Systems Theory and Automatic Control at the Institute for Automation Engineering (IFAT) of the Otto von Guericke Universit...
12.08.2019 | Curetis GmbH

Curetis Retains H.C. Wainwright & Co. as Strategic Advisor

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has retained the U.S. based investment bank, H.C. Wainwright & Co., LLC, as strategic a...
08.08.2019 | Curetis GmbH

Curetis Group Company Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its wholly-own...
17.07.2019 | Atriva Therapeutics GmbH

Atriva Therapeutics Receives EU Award for Biomarker Validation

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME. A total...
12.07.2019

Towards personalized medicine: 5 West-Holland companies get support from Codex4SME’s

The Interreg project Codex4SMEs (Companion diagnostics expedited for small and medium-sized businesses) project plans to improve healthcare by enhanced adoption of Person...
08.07.2019 | immatics biotechnologies GmbH

Immatics Appoints Harpreet Singh as Chief Executive Officer

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Offic...
04.07.2019 | Curetis GmbH

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic resistance, First of eleven similar patents filed covering various pathogen/drug...
01.07.2019 | CureVac AG

European Commission Appoints CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, to the European Innovation Council Advisory Board

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, congratulates CureVac co-founder and Chairman of the Supervisory Board,...
23.05.2019 | Curetis GmbH

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced key data from its succe...
21.05.2019 | Curetis GmbH

Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Curetis will recei...
17.05.2019 | Curetis GmbH

Curetis Announces Financial Results for the First Three Months of 2019

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first threemonths ended March31, 2019,and provided a business update f...
15.05.2019 | Atriva Therapeutics GmbH

Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against Influenza

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first dosing of its lead drug ...
09.04.2019 | immatics biotechnologies GmbH

Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA203, its third T...
04.04.2019

Retina Implant AG discontinues business activities

Unfortunately, the history of our company is coming to an end. The shareholders of Retina Implant AG resolved to dissolve the company at an extraordinary general meeting held on 19 March 2019.

02.04.2019 | Curetis GmbH

Curetis Introduces Unyvero AMR Atlas to Support Adoption of Rapid DNATesting for Antibiotic Resistance

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it will introd...
26.03.2019 | Curetis GmbH

Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has entered...